Based on a bioinformatics analysis in our previous work, we suggest HLA-E as a potential therapeutic target for the treatment of MM (9) and designed peptides to bind HLA-E by analyzing its interaction with CD94/NKG2A. This evidence concerns the gene KLRC1 and Miyoshi myopathy.